The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC

Active:	No
Cancer Type:	Head and Neck Cancer Skin Cancer (Non-Melanoma) Unknown Primary	NCT ID:	NCT04338399
Trial Phases:	Phase III	Protocol IDs:	AN2025H0301 (primary) NCI-2021-07462
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Adlai Nortye Biopharma Co., Ltd.
NCI Full Details:	http://clinicaltrials.gov/show/NCT04338399

Summary

The BURAN study is a randomized, open-label phase III study to assess the treatment
effect of once-daily buparlisib in combination with weekly paclitaxel compared to weekly
paclitaxel alone in patients with refractory, recurrent, or metastatic head and neck
squamous cell carcinoma (HNSCC) that have progressed after prior anti PD 1/anti PD L1
monotherapy; prior anti PD 1/anti PD L1 therapy in combination with platinum-based
therapy; or after sequential treatment of anti PD 1/anti PD L1 therapy, either prior to
or post, platinum-based therapy.

Objectives

This study is to assess the impact on overall survival of the combination of Buparlisib
and paclitaxel compared to paclitaxel alone in patients with prior anti PD 1/anti PD L1
monotherapy; prior anti PD 1/anti PD L1 therapy in combination with platinum-based
therapy; or after sequential treatment of anti PD 1/anti PD L1 therapy, either prior to
or post, platinum-based therapy.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.